Conduit Pharmaceuticals Inc. (CDT) - Net Assets
Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) has net assets worth $1.28 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.46 Billion) and total liabilities ($2.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CDT tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.28 Billion |
| % of Total Assets | 37.09% |
| Annual Growth Rate | 1473.64% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Conduit Pharmaceuticals Inc. - Net Assets Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s net assets have evolved over time, based on quarterly financial data. See Conduit Pharmaceuticals Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual net assets of Conduit Pharmaceuticals Inc. from 2021 to 2025. For live valuation and market cap data, see CDT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.26 Billion | +18713.63% |
| 2024-12-31 | $-6.79 Million | -1386.43% |
| 2023-12-31 | $-457.00K | +95.47% |
| 2022-12-31 | $-10.09 Million | -49030.60% |
| 2021-12-31 | $20.62K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Conduit Pharmaceuticals Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 140557638100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.41 Billion | 111.16% |
| Common Stock | $503.00K | 0.04% |
| Other Comprehensive Income | $-97.20 Million | -7.69% |
| Total Equity | $1.26 Billion | 100.00% |
Conduit Pharmaceuticals Inc. Competitors by Market Cap
The table below lists competitors of Conduit Pharmaceuticals Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DSJ Keep Learning Limited
NSE:KEEPLEARN
|
$3.37 Million |
|
Inomin Mines Inc
V:MINE
|
$3.37 Million |
|
Krida Jaringan Nusantara Tbk PT
JK:KJEN
|
$3.37 Million |
|
Delixy Holdings Limited Ordinary Shares
NASDAQ:DLXY
|
$3.37 Million |
|
HITIQ Ltd
AU:HIQ
|
$3.36 Million |
|
Marula Mining PLC
F:48U0
|
$3.36 Million |
|
Mynaric AG
XETRA:M0YN
|
$3.36 Million |
|
Summit Minerals Ltd
AU:SUM
|
$3.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Conduit Pharmaceuticals Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -6,793,000 to 1,264,424,000, a change of 1,271,217,000.
- Net loss of 39,224,000 reduced equity.
- Dividend payments of 7,966,000 reduced retained earnings.
- Share repurchases of 106,000 reduced equity.
- New share issuances of 19,699,000 increased equity.
- Other comprehensive income decreased equity by 97,618,000.
- Other factors increased equity by 1,396,432,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.22 Million | -3.1% |
| Dividends Paid | $7.97 Million | -0.63% |
| Share Repurchases | $106.00K | -0.01% |
| Share Issuances | $19.70 Million | +1.56% |
| Other Comprehensive Income | $-97.62 Million | -7.72% |
| Other Changes | $1.40 Billion | +110.44% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Conduit Pharmaceuticals Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $86.06 | $0.69 | x |
| 2022-12-31 | $-7631.45 | $0.69 | x |
| 2023-12-31 | $-80.77 | $0.69 | x |
| 2024-12-31 | $-940.10 | $0.69 | x |
| 2025-12-31 | $37970.69 | $0.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Conduit Pharmaceuticals Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.44%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 2.80x
- Recent ROE (-3.10%) is above the historical average (-3547.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -17736.07% | 0.00% | 0.00x | 10.34x | $-3.66 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.88 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-489.30K |
| 2024 | 0.00% | -1.93% | 219.94x | 0.00x | $-17.12 Million |
| 2025 | -3.10% | -1.44% | 0.77x | 2.80x | $-165.67 Million |
Industry Comparison
This section compares Conduit Pharmaceuticals Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Conduit Pharmaceuticals Inc. (CDT) | $1.28 Billion | -17736.07% | 1.70x | $3.37 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more